Skip to main content
Premium Trial:

Request an Annual Quote

Cengent Inks Drug Discovery Collaboration with Novartis Institutes

NEW YORK, April 12 (GenomeWeb News) - Cengent Therapeutics said today that it has struck a drug discovery deal with the Novartis Institutes for Biomedical Research.

 

Under the deal, Cengent said it will use its proprietary structure-based lead identification technology to screen for drug candidates against targets identified by the Novartis Institutes.

 

Financial terms of the deal were not disclosed, but Cengent said the arrangement includes upfront and milestone payments.

 

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.